Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

The Best and Worst Antipsychotics for Mania - Part 2, 2021-10-25

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

ex9902004.jpg

ex99-01_img005.jpg

ex9902009.jpg

Brexpiprazole Warnings: Side Effects of Rexulti

Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human

Table 2 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

1mg REXULTI TABLET, Schizophrenia, Intas Pharmaceuticals

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent

Dichlorophenyl piperazines, including a recently-approved atypical antipsychotic, are potent inhibitors of DHCR7, the last enzyme in cholesterol biosynthesis. - Abstract - Europe PMC

PDF) Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole

The Visual Illusion of Efficacy in Psychiatric Drug Trials - Mad In America

Full article: Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human